Tarsus Pharmaceuticals, Inc. (TARS)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $3.43B
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 3, 2026
Profit #1437 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | -21.2% | -26.0% | -48.4% | -71.0% |
Growth #6 of 1484 companies
Payout #1117 of 1484 companies
Safety #984 of 1484 companies
Price #1284 of 1484 companies
